Results 241 to 250 of about 68,056 (282)

Extent of Resection Thresholds in Molecular Subgroups of Newly Diagnosed Isocitrate Dehydrogenase-Wildtype Glioblastoma. [PDF]

Neurosurgery
Dono A, Zhu P, Takayasu T, Arevalo O, Riascos R, Tandon N, Ballester LY, Esquenazi Y.   +7 more
europepmc   +1 more source

Mapping tumor habitats in isocitrate dehydrogenase -wild type glioblastoma: Integrating MRI, pathologic, and RNA data from the Ivy Glioblastoma Atlas Project. [PDF]

Neuro Oncol
Park JE, Oh JY, Park DH, Lee HS, Yoon S, Kim N, Park SY, Song SW, Kim YH, Hong CK, Kim JH, Kim HS.   +11 more
europepmc   +1 more source

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond. [PDF]

Am Soc Clin Oncol Educ Book
Schaff LR, Ioannou M, Geurts M, van den Bent MJ, Mellinghoff IK, Schreck KC.   +5 more
europepmc   +1 more source

Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. [PDF]

Leukemia
Fruchtman H, Avigan ZM, Waksal JA, Brennan N, Mascarenhas JO.   +4 more
europepmc   +1 more source

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases. [PDF]

Front Pharmacol
Peng M, Guo Q, Dang Z, Zhang B, Li M, Wang Z, Lu X, Lin J.   +7 more
europepmc   +1 more source

Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma. [PDF]

Acta Neuropathol
Weller M, Felsberg J, Hentschel B, Gramatzki D, Kubon N, Wolter M, Reusche M, Roth P, Krex D, Herrlinger U, Westphal M, Tonn JC, Regli L, Maurage CA, von Deimling A, Pietsch T, Le Rhun E, Reifenberger G.   +17 more
europepmc   +1 more source

Preparation and Preclinical Evaluation of ¹⁸F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1). [PDF]

Molecules
Cologni R, Holschbach M, Schneider D, Bier D, Schulze A, Stegmayr C, Endepols H, Ermert J, Neumaier F, Neumaier B.   +9 more
europepmc   +1 more source